131 related articles for article (PubMed ID: 3788420)
1. Serum thyroid autoantibodies as a risk factor for development of hypothyroidism after radioactive iodine therapy for single thyroid 'hot' nodule.
Mariotti S; Martino E; Francesconi M; Ceccarelli C; Grasso L; Lippi F; Baschieri L; Pinchera A
Acta Endocrinol (Copenh); 1986 Dec; 113(4):500-7. PubMed ID: 3788420
[TBL] [Abstract][Full Text] [Related]
2. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study.
Ceccarelli C; Bencivelli W; Vitti P; Grasso L; Pinchera A
Clin Endocrinol (Oxf); 2005 Mar; 62(3):331-5. PubMed ID: 15730415
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
4. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
5. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
[TBL] [Abstract][Full Text] [Related]
6. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre.
Le Moli R; Wesche MF; Tiel-Van Buul MM; Wiersinga WM
Clin Endocrinol (Oxf); 1999 Jun; 50(6):783-9. PubMed ID: 10468951
[TBL] [Abstract][Full Text] [Related]
7. Hypothyroidism following 131I therapy for hyperthyroidism in relation to immunologic parameters.
Lundell G; Holm LE
Acta Radiol Oncol; 1980; 19(6):449-54. PubMed ID: 6263058
[TBL] [Abstract][Full Text] [Related]
8. The incidence of hypothyroidism after radioactive iodine (131I) therapy for autonomous hyperfunctioning thyroid nodule evaluated by means of life-table method.
Fontana B; Curti G; Biggi A; Fresco G
J Nucl Med Allied Sci; 1980; 24(1-2):85-91. PubMed ID: 7205395
[No Abstract] [Full Text] [Related]
9. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
11. Hypothyroidism after iodine-131 or surgical therapy for Graves' disease hyperthyroidism.
Gómez JM; Gómez N; Amat M; Biondo S; Rafecas A; Jaurrieta E; Soler J
Ann Endocrinol (Paris); 2000 Sep; 61(3):184-91. PubMed ID: 10970941
[TBL] [Abstract][Full Text] [Related]
12. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
13. 131I treated hypothyroidism and thyroid antibody levels.
Vejjajiva S; Poshyachinda M; Yenbutra D
J Med Assoc Thai; 1979 Feb; 62(2):51-3. PubMed ID: 762484
[No Abstract] [Full Text] [Related]
14. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Hypothyroidism Following Empirical Dose Radioiodine in Toxic Thyroid Nodules: Real-Life Experience.
Demir BK; Karakilic E; Saygili ES; Araci N; Ozdemir S
Endocr Pract; 2022 Aug; 28(8):749-753. PubMed ID: 35537668
[TBL] [Abstract][Full Text] [Related]
16. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism.
Marcocci C; Gianchecchi D; Masini I; Golia F; Ceccarelli C; Bracci E; Fenzi GF; Pinchera A
J Endocrinol Invest; 1990 Jun; 13(6):513-20. PubMed ID: 2258580
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
18. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
[TBL] [Abstract][Full Text] [Related]
19. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]